GSK plc 6-K, filed Aug 25, 2023
GSK plc (GSK)
6-K
2023-08-25
For: 2023-08-25
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on August 25, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Hal Barron
|
|||
|
b)
|
Position/status
|
Non-Executive Director
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
The vesting of an award in the form of a nil-cost option over ADSs
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
and the subsequent exercise of the nil-cost option
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
..
|
36,090
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-08-24
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Hal Barron
|
|||
|
b)
|
Position/status
|
Non-Executive Director
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the exercise
of a nil-cost option award granted in 2020 under the Company's 2017
Deferred Annual Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.6174
..
|
19,446
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-08-24
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Hal Barron
|
|||
|
b)
|
Position/status
|
Non-Executive Director
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
|
107,937
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-08-24
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Hal Barron
|
|||
|
b)
|
Position/status
|
Non-Executive Director
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044s
|
|||
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.6174
|
58,157
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-08-24
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
25, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|